- Home
- KZIA vs GLTO Comparison
KZIA vs GLTO Comparison
Compare KZIA & GLTO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- KZIA
- GLTO
- Stock Information
- Founded
- KZIA 1994
- GLTO 2011
- Country
- KZIA Australia
- GLTO Denmark
- Employees
- KZIA N/A
- GLTO N/A
- Industry
- KZIA Biotechnology: Pharmaceutical Preparations
- GLTO Biotechnology: Pharmaceutical Preparations
- Sector
- KZIA Health Care
- GLTO Health Care
- Exchange
- KZIA Nasdaq
- GLTO Nasdaq
- Market Cap
- KZIA 11.7M
- GLTO 23.7M
- IPO Year
- KZIA 1999
- GLTO 2020
- Fundamental
- Price
- KZIA $7.52
- GLTO $5.72
- Analyst Decision
- KZIA Strong Buy
- GLTO
- Analyst Count
- KZIA 3
- GLTO 0
- Target Price
- KZIA $16.00
- GLTO N/A
- AVG Volume (30 Days)
- KZIA 73.2K
- GLTO 126.6K
- Earning Date
- KZIA 12-26-2025
- GLTO 11-04-2025
- Dividend Yield
- KZIA N/A
- GLTO N/A
- EPS Growth
- KZIA N/A
- GLTO N/A
- EPS
- KZIA N/A
- GLTO N/A
- Revenue
- KZIA $1,549,158.00
- GLTO N/A
- Revenue This Year
- KZIA N/A
- GLTO N/A
- Revenue Next Year
- KZIA N/A
- GLTO N/A
- P/E Ratio
- KZIA N/A
- GLTO N/A
- Revenue Growth
- KZIA 248983.08
- GLTO N/A
- 52 Week Low
- KZIA $2.86
- GLTO $2.01
- 52 Week High
- KZIA $34.80
- GLTO $31.70
- Technical
- Relative Strength Index (RSI)
- KZIA 52.85
- GLTO 42.06
- Support Level
- KZIA $7.37
- GLTO $7.02
- Resistance Level
- KZIA $8.02
- GLTO $7.64
- Average True Range (ATR)
- KZIA 0.46
- GLTO 0.58
- MACD
- KZIA 0.07
- GLTO -0.55
- Stochastic Oscillator
- KZIA 66.89
- GLTO 0.50
About KZIA Kazia Therapeutics Limited
Kazia Therapeutics Ltd is an oncology-focused biotechnology company, developing anti-cancer drugs. The group is developing paxalisib, a potential treatment for glioblastoma; Cantrixil, being developed for the treatment of ovarian cancer; and Others. The company is also developing EVT801 for the treatment of various tumors. Maximum of revenue is earned from South Korea.
About GLTO Galecto Inc.
Galecto Inc is a clinical-stage biotechnology company developing therapeutics designed to target the biological processes that lie at the heart of cancer and liver diseases. Its initial focus is on the development of small-molecule inhibitors of galectin-3 and lysyl oxidase-like 2, or LOXL2. Its product candidate GB0139 is for the treatment of severe fibrotic lung diseases such as idiopathic pulmonary fibrosis, or IPF, a life-threatening progressive fibrotic disease of the lung. Its product GB1211, a selective oral galectin-3 inhibitor for the treatment of fibrosis related to non-alcoholic steatohepatitis, or NASH, and GB2064, a selective oral inhibitor of LOXL2 that it initially plans to develop for the treatment of myelofibrosis.